These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30069922)

  • 21. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
    Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
    Rasool RU; Natesan R; Deng Q; Aras S; Lal P; Sander Effron S; Mitchell-Velasquez E; Posimo JM; Carskadon S; Baca SC; Pomerantz MM; Siddiqui J; Schwartz LE; Lee DJ; Palanisamy N; Narla G; Den RB; Freedman ML; Brady DC; Asangani IA
    Cancer Discov; 2019 Nov; 9(11):1538-1555. PubMed ID: 31466944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.
    He Y; Peng S; Wang J; Chen H; Cong X; Chen A; Hu M; Qin M; Wu H; Gao S; Wang L; Wang X; Yi Z; Liu M
    Nat Commun; 2016 Dec; 7():13122. PubMed ID: 27959342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
    Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
    Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
    Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
    FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    Semaan L; Mander N; Cher ML; Chinni SR
    BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
    Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.
    Cao B; Qi Y; Yang Y; Liu X; Xu D; Guo W; Zhan Y; Xiong Z; Zhang A; Wang AR; Fu X; Zhang H; Zhao L; Gu J; Dong Y
    PLoS One; 2014; 9(11):e111201. PubMed ID: 25375370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
    Toren PJ; Kim S; Pham S; Mangalji A; Adomat H; Guns ES; Zoubeidi A; Moore W; Gleave ME
    Mol Cancer Ther; 2015 Jan; 14(1):59-69. PubMed ID: 25351916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
    Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
    Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.